Related Experiment Videos
A CD14 domain with lipopolysaccharide-binding and -neutralizing activity.
Söhnke Voss1, Stefan Welte, Mariola Fotin-Mleczek
1Institute for Cell Biology, Department of Molecular Biology, University of Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Chembiochem : a European Journal of Chemical Biology
|January 31, 2006
Summary
Researchers identified a new lipopolysaccharide-binding domain on the CD14 protein. This domain, crucial for neutralizing lipopolysaccharide (LPS) activity, offers potential for developing new sepsis treatments.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Lipopolysaccharide (LPS) interaction with CD14 is vital for pathogen defense but also implicated in sepsis development.
- Understanding CD14's LPS-binding mechanism is critical for therapeutic intervention.
Purpose of the Study:
- To map the CD14 protein and identify specific domains involved in lipopolysaccharide binding.
- To characterize the structure-activity relationship of a novel LPS-neutralizing peptide derived from CD14.
- To explore the potential of this peptide for developing enhanced therapeutic agents.
Main Methods:
- Peptide mapping of the full-length CD14 protein using synthetic 20-amino-acid peptides.
- Structure-activity relationship analysis of identified CD14 peptides.
- Site-directed mutagenesis to create mutant CD14 proteins lacking LPS-binding capacity.
- Assessment of LPS-neutralizing activity in vitro and in cellular models.
Main Results:
- A novel lipopolysaccharide-binding domain within CD14 was identified, exhibiting potent LPS-neutralizing activity.
- A specific peptide (amino acids 81-100) was found to be responsible for this activity, with key leucine residues (87, 91, 94) being essential.
- Mutant CD14 proteins confirmed the functional importance of these residues in LPS binding.
- The identified peptide served as a foundation for developing more soluble and potent LPS-neutralizing analogues.
Conclusions:
- A functionally significant LPS-binding and neutralizing domain within CD14 has been characterized.
- Targeting this domain, particularly the identified peptide and its analogues, holds promise for novel therapeutic strategies against LPS-mediated inflammatory conditions like sepsis.